

Special Issue

Next-Generation Pertussis Vaccines

Message from the Guest Editors

The incidence of pertussis is increasing in many countries, especially those using acellular pertussis (aP) vaccines, and this has resulted in renewed research focus on a disease that was once thought to be on the way out. There are several possible reasons for the return of pertussis, including: (1) waning of protective immunity following immunization with aP vaccines, (2) evolution of strain due to vaccine-driven immune selection pressure, (3) a failure of aP vaccines to induce effective T cell response, and (4) the inability of aP vaccines to block nasal colonization and transmission of *B. pertussis*. There is general agreement that we need to develop a “next generation” pertussis vaccine; however, there is no clear roadmap for their development, but it is clear that it must solve some of the issues with the current one. Since the solutions are not obvious, we would like to invite cutting-edge manuscripts for a Special Issue of *Vaccines* on ‘Next-Generation Pertussis Vaccines’. We invite authors to contribute original articles or reviews that address this public health concern.

Guest Editors

Prof. Kingston Mills

Trinity Biomedical Sciences Institute, Dublin, Ireland

Dr. F. Heath Damron

Department of Microbiology, Immunology & Cell Biology, School of Medicine, West Virginia University, Morgantown, WV 26506, USA

Deadline for manuscript submissions

closed (30 September 2020)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/32333

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).